Lupin rose 2.38% to Rs 735.55 after the company said it received US drug regulator's approval for Zileuton extended-release tablets in the United States.
Pharma major Lupin announced that it has received approval from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Zyflo CR extended-release tablets, 600 mg, of Chiesi USA, Inc.Lupin's Zileuton extended-release tablets, 600 mg are indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton (600 mg) had annual sales of approximately $43 million in the US. (IQVIA MAT September 2019). The announcement was made after trading hours on Friday, 8 November 2019.
Shares of Lupin fell 6.95% in the past two trading sessions to settle at Rs 718.45 on Friday, 8 November 2019, from its close of Rs 772.15 on 6 November 2019.
Lupin's consolidated net profit soared 37.1% to Rs 364.53 crore on 10.4% rise in net sales to Rs 4,296.90 crore in Q2 September 2019 over Q2 September 2018.
Lupin is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app